tbuckley/cabot-search huggingface dataset:
APPLE News
Journal: Liver Cancer (2020)

AimsPrimary liver cancer is an extremely malignant disease, and 80% of patients are found in Asian countries.e APPLE Meetings have been initiated to provide a platform for regional and international experts to exchange information on the latest advancements in primary liver cancer treatment.e meetings are aimed at bridging gaps in the basic science and clinical aspects of liver cancer among specialists, with the ultimate aim of disseminating the results of laboratory research and clinical trials in liver cancer among professionals. Histor ye APPLE Meetings take place annually and have been hosted on rotation by the Korean Liver Cancer Study Group, the Liver Cancer Study Group of Japan, and the Chinese Liver Cancer Study Group.e 1st meeting of the group took place in Incheon in 2010, the 2nd in Osaka in 2011, the 3rd in Shanghai in 2012, and the 4th in Busan in 2013.In 2014, APPLE changed its policy and decided to expand its congress venues from three countries to include all Asian countries, and the 5th APPLE Meeting was held in Taipei in 2014.
Untersuchungen über die Harnsteine.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adrenal insufficiency due to cryptococcosis
Authors: B. Shah
Journal: JAMA (1986)

UNTIL the mid-1930s, tuberculosis had traditionally been considered to be the most frequent cause of primary adrenal insufficiency. With a progressive decrease in the prevalence of this granulomatous process, however, autoimmune disease has superseded tuberculosis as the most frequent cause of primary adrenal insufficiency.<sup>1</sup>It is amply documented, nevertheless, that certain fungal diseases such as histoplasmosis as well as neoplasms may destroy sufficient adrenal tissue to produce the signs and symptoms of Addison's disease.<sup>2-4</sup>It is our purpose herein to point out the less well-known fact that other fungal diseases, by means of massive destruction of the adrenal glands, may likewise produce adrenal insufficiency. Specifically, we detail what to the best of our knowledge is the second reported, antemortem biochemically and histopathologically confirmed documentation of cryptococcal-induced adrenal cortical insufficiency. We likewise point out the value of computed tomographic (CT) scanning of the adrenal glands to assist in the
Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome
Authors: K. M. Leiferman
Journal: JAMA (1982)

The hypereosinophilic syndrome is a multisystem disease characterized by infiltration of eosinophils in bone marrow, heart, and other organs. Cutaneous involvement occurs, but usually it appears late in the disease and is of less importance than the cardiac and other organ involvement. We describe two patients with the hypereosinophilic syndrome (HES) in whom the initial manifestations of the disease were recurrent, severe mucosal ulcers involving the mouth and genitalia. In both patients, the mucosal involvement antedated the cardiac manifestations of the disease, and in both, the disease was refractory to treatment. (<i>JAMA</i>1982;247:1018-1020)
Medical News: London Letter
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Insulin Resistance Syndrome and Echocardiographic Left Ventricular Mass in African-Americans
Authors: Cecil M Burchfiel, Thomas N Skelton, Michael E Andrew, Robert J Garrison, Donna K Arnett, Daniel W Jones, Herman A Taylor
Journal: Circulation (2001)

P70 The insulin resistance syndrome (IRS) has been associated with cardiovascular disease (CVD), but few studies have examined its relationship with subclinical measures such as echocardiographic left ventricular (LV) mass. This relationship is likely to be of particular importance in African-Americans where both IRS and elevated LV mass are common. Complete information was available for 1633 African-American women and men aged 49-73 who were enrolled in the Atherosclerosis Risk in Communities (ARIC) Study when M-mode echocardiography was performed at one of the four ARIC sites in Jackson, Mississippi (1993-1996). LV mass was calculated according to American Society of Echocardiography methods using the cube formula and was indexed by height. Participants were categorized by the number (0, 1, 2, or 3) of IRS characteristics (hypertension, dyslipidemia (low HDL cholesterol or high triglyceride), and glucose intolerance (diabetes or fasting glucose values ≥110 mg/dl)). Age-adjusted mean LV mass/height (g/m) increased progressively with increasing number of IRS disorders in both women and men (128.9, 148.6, 161.0, 171.6 and 135.9, 157.4, 170.6, 171.6 respectively, p&lt;0.001, tests for trend). Associations were slightly stronger in women than in men and were similar when participants were stratified by age, BMI and waist circumference. These associations were not altered by adjustment for smoking and alcohol intake, and were only slightly attenuated with adjustment for BMI and waist circumference. Analyses focusing on the components of LV mass revealed that posterior wall and interventricular septal thickness, but not LV chamber size, were significantly associated with the number of IRS disorders. In this large population-based study of middle-aged African-American women and men the degree of IRS clustering was strongly and independently related to LV mass and these associations are consistent with a possible influence of insulin resistance on myocardial thickening rather than chamber size.
OFFICIAL CALL
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dantrolene hepatitis
Authors: R. Schneider
Journal: JAMA (1976)

DANTROLENE SODIUM is a new orally administered hydantoin derivative that is useful in control of skeletal muscle spasticity.<sup>1,2</sup>Known adverse effects include drowsiness, dizziness, nausea, vomiting, diarrhea, headache, and general malaise. To date, there have been no published reports of severe hepatic toxicity in association with the drug,<sup>3</sup>although minor abnormalities of liver function have been observed in a sizeable percentage of recipients.<sup>4,5</sup>Recently, the drug company has changed the package insert to warn of potential hepatic toxicity. We report a patient with dantrolene hepatitis who had deep jaundice. <h3>Report of a Case</h3> A 38-year-old woman who had had weakness and spasticity of her legs for four years was considered to have multiple sclerosis. In April 1974, dantrolene sodium therapy was started and was gradually increased to a dosage of 400 mg/day, which was continued until Aug 13, 1974. The only other drugs she was taking were cod
Anticancer Drugs Applied Topically for Skin Tumors
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
T-lymphocyte subsets in intravenous drug users with HIV-1 infection
Authors: W. Winkelstein
Journal: JAMA (1992)

<h3>To the Editor.</h3> —Recently, Margolick et al<sup>1</sup>reported on changes in CD4 and CD8 T-lymphocyte subsets in intravenous drug users (IVDUs). In their words, "The principal finding was the slow rate of decline in CD4 lymphocyte counts in HIV-1 [human immunodeficiency virus type 1] seropositive IVDUs over a 2.5-year period of observation." (Actual observation period was 18 months.) The authors assert that this finding contradicts "the common perception that HIV-1 infection in IVDUs leads to rapid decline in CD4 lymphocytes." Howev Follow-up, Acquired Immunodeficiency Syndrome (AIDS) Incidence, and Rates of Change in CD4<sup>+</sup>Lymphocyte Numbers in the San Giovanni Hospital Subcohort of the MPH Study, by CD4<sup>+</sup>Lymphocyte Level at Baseline* Baseline CD4 Level, Cells/μL Developed AIDS No. (%) Incidence† Median Follow-up, Semesters 1.16 Changes/6 mo Median Mean &lt;150 4(44) 34.36 -42.92 10.90 150-299 20 4(20) 2.08 2.42 6.25 23.80 26 6(23) 6.37 -15.31 450-599 45 6(13) 3.19 3.66 -29.79
Selected Pesticide Residues or Metabolites in Blood and Urine Specimens from a General Population Survey
Authors: Robert S. Murphy, Fredrick W. Kutz, Sandra C. Strassman
Journal: Environmental Health Perspectives (1983)

The National Center for Health Statistics collaborated with the National Human Monitoring Program of the U.S. Environmental Protection Agency (EPA) in a four-year study to assess the exposure of the general population to selected pesticides through analysis of blood serum and urine specimens. Specimens were collected on a national probability half sample of persons 12-74 years of age from 64 locations across the United States comprising the sample areas in the Second Health and Nutrition Examination Survey (NHANES II) and analyzed for selected organochlorine, carbamate, chlorophenoxy and organophosphorus pesticides. Medical, nutritional and pesticide usage data are also available for each sample person. Preliminary results of the blood serum and urine analyses indicate that the general population is being exposed to some of these types of pesticides. Since 1970, EPA has conducted a national probability sampling of human adipose tissue. Specimens obtained on a survey design representative of the general population were analyzed for selected organochlorine pesticides and toxic chemicals. Findings from the 1978 survey also indicate exposure of the general population to some of these chemicals. Medical data collected from both surveys have yielded no overt correlations between health effects and residue levels. More intensive statistical analyses are underway to investigate the possible existence of more subtle relationships.
Practice of Surgery: Clinical, Diagnostic, Operative, and Postoperative.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Authors' response
Authors: Vidya Navaratnam, Kate M Fleming, Joe West, C J P Smith, R G Jenkins, Andrew W Fogarty, Richard Hubbard
Journal: Thorax (2011)

to patients and colleagues responsible for acutely ill patients with COPD.In keeping with the NICE guidelines, COPD severity should be described in terms of functional status using at least the modified MRC score, as well as previous severity of lung function impairment.It should be made clear that the severity of lung function impairment in COPD does not necessarily correlate with clinical severity or outcome of inpatient care, which may include ITU and IMV management.
Erratum to: Derks JL, Leblay N, Lantuejoul S, Dingemans A-M, Speel, E-JM, Fernandez-Cuesta L. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13(6):752-766.
Journal: Journal of Thoracic Oncology (2018)
ECZEMA
Authors: JOHN T. INGRAM
Journal: British Journal of Dermatology (1935)

Journal Article ECZEMA Get access JOHN T. INGRAM, M.D.Lond., M.R.C.P.Lond. JOHN T. INGRAM, M.D.Lond., M.R.C.P.Lond. Leeds Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 47, Issue 2, 1 February 1935, Pages 64–69, https://doi.org/10.1111/j.1365-2133.1935.tb09832.x Published: 01 February 1935
Abstract 1079: Prevention of Fatal Arrhythmia in a Catecholaminergic Polymorphic Ventricular Tachycardia Mouse Model Carrying Calsequestrin-2 Mutation
Authors: Hiroko Wakimoto, Ronny Alcalai, Lei Song, Michael Arad, Christine E Seidman, Jonathan G Seidman, Charles I Berul
Journal: Circulation (2007)

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial arrhythmia syndrome caused by mutations in the ryanodine receptor (RyR2) or calsequestrin-2 (CASQ2) genes and characterized by exercise or emotional stress-induced sudden death. Beta-adrenergic blockers are only partially effective and other agents have not been widely tested. Recent studies have shown that CPVT is mediated by increased Ca 2+ leak through the RyR2 channel. Our aim was to determine whether agents that inhibit intracellular Ca 2+ leak can effectively prevent CPVT. Methods: The efficacy of intraperitoneal (IP) propranolol (1mcg/g), Mg 2+ (0.002mEq/g), verapamil (8 mcg/g) and diltiazem (8 mcg/g) were tested both in vivo and in vitro using CASQ2 mutant mouse CPVT model. In vivo studies included ambulatory ECG recordings at rest and following epinephrine stress (0.4 mcg/g IP) at baseline and after study drug administration. Experiments for each drug were performed on separate days to avoid confounding effects. In vitro studies included intracellular Ca 2+ transient analysis on isolated cardiomyocytes from mutant mice with and without epinephrine (5.5 μM). Results: All 4 drugs restored sinus rhythm and reduced the frequency of VT episodes induced by epinephrine in CASQ2 mutant mice. Only verapamil completely prevented epinephrine-induced VT in 87% of the mice (p&lt;0.01). Cardiomyocyte studies in basal conditions revealed that Mg 2+ and verapamil inhibited sarcomere contraction and normalized the prolonged Ca 2+ reuptake period in CASQ2 mutants, but did not decrease baseline Ca 2+ peak height. Epinephrine-stressed mutant myocytes had increased diastolic Ca 2+ levels, lower Ca 2+ peak height and spontaneous SR Ca 2+ release events that were partially prevented by verapamil and Mg 2+ . Verapamil was more effective than Mg 2+ in reducing the frequency of spontaneous Ca 2+ releases induced by epinephrine. Conclusions: All 4 agents can inhibit ventricular arrhythmia in CPVT mouse model; however verapamil appears most effective in preventing arrhythmia in vivo and in modifying intracellular abnormal calcium handling. Calcium antagonists might have therapeutic value in CPVT and other RyR2-mediated arrhythmias and should be considered for human clinical studies.
Informed consent in resuscitation research
Authors: N. S. Abramson
Journal: JAMA (1981)

SCIENTIFICALLY proved advances in care of the critically ill patient are expected, accepted, and perhaps even demanded by society. This is illustrated by the tremendous growth in federal funding for National Institutes of Health (NIH)-sponsored biomedical research between 1945 and 1965.<sup>1</sup>However, the resulting medical advances have produced unanticipated ethical and legal problems. In this article, we address the emerging conflict between two restraints on clinical research: (1) the assurance of scientifically valid results and (2) the protection of the human rights of research subjects. This conflict is particularly acute in resuscitation research, where immediate medical intervention is necessary and the potential research subjects are comatose. <h3>THE CONFLICT</h3> At present all biomedical and behavioral research supported by federal funds must conform to legal requirements promulgated by the Department of Health and Human Services (DHHS).<sup>2</sup>(New DHHS regulations were issued July 27, 1981.<sup>3</sup>They are complemented by new
Electroencephalographic Findings in Unilateral Cerebral Atrophy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel –Study informing treatment Pathway dEcisions in Merkel cell cARcinoma (MCC).
Authors: Charles Lance Cowey, Frank Xiaoqing Liu, Ruth Kim, Marley Boyd, Nicole Fulcher, Stan Krulewicz, Vijay Kasturi, Abhijeet Bhanegaonkar
Journal: Journal of Clinical Oncology (2020)

e22029 Background: MCC is a rare, aggressive disease associated with poor prognosis. Avelumab, a fully human anti–PD-L1 monoclonal antibody, was the first immune checkpoint inhibitor approved by the FDA for the treatment of metastatic MCC (mMCC). In the JAVELIN Merkel 200 trial (Clinical trial information: NCT02155647), avelumab resulted in durable responses and a high objective response rate (ORR) in pts with mMCC. This retrospective descriptive study assessed real-world clinical outcomes in avelumab-treated pts with locally advanced MCC (laMCC) and mMCC in a US community oncology setting. Methods: This study included data on avelumab-treated laMCC and mMCC pts from 1/1/17 to 3/31/19 within The US Oncology Network. Study data were captured through 9/30/19 using structured fields and chart review of iKnowMed electronic healthcare records. Real-world ORR was assessed. Duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Results: 33 pts initiated treatment with avelumab (laMCC n = 11; mMCC n = 22) and were followed up for a median of 10.9 months (range, 0.5-27.2 months). Median age was 77 years (range, 44-90+ years), 78.8% of pts were male, and the majority (84.8%) of pts were treated in the first-line setting. During treatment, 27.2% of pts had emergency department visits and 39.4% were hospitalized; 1% and 23.1%, respectively, were treatment related. Clinical outcomes are reported in the table. Conclusions: This is the first study to examine pts with laMCC treated with avelumab in a real-world setting. Although the sample population is small, results suggest the clinical benefits in the real world in pts with mMCC treated with avelumab are consistent with benefits reported in the JAVELIN Merkel 200 trial. Clinical trial information: NCT02155647 . [Table: see text]